Good Citizen of the Research Community

The Baptist Health research team offers a number of services that are vital to the success of clinical research and testing:

• Participation in federal and commercially sponsored trials that provide new treatment opportunities for a variety of medical conditions and diseases 
• Research coordination 
• Trial-matching patients to studies taking place both inside and outside Baptist Health 
• Collaboration with other hospitals and treatment centers to find the best possible fit between patients and research initiatives

Areas of Emphasis

Baptist Health Louisville has been involved in several groundbreaking research programs. Many of the therapies and drugs tested by our oncology program have become “gold-standard treatments” in the fight against cancer. In addition, we were recently awarded a federal grant to evaluate medical decision-making in the treatment of heart failure; a research project that we hope will improve the outcomes of patients both at Baptist Health and in the world at large.

Program Highlights

Below are highlights of some of the research being conducted at Baptist Health Louisville:

Cancer Trials:

• A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma
• NRG BR-003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
• NRG BR-004: Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
• TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression
• Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
• RTOG-0724: Phase III Randomized Study Of Concurrent Chemotherapy And Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma
• S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
• DS1062AU301: Phase 3 Randomized Study of DS-1062a Versus Docetaxel in previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung01)
• AB154CSP0002: A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer   
• NRG-LU005: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab      

Cardiac Care:

• FLASH: Registry trial to evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE)
• DECIDE: A Multicenter Trial of a Shared Decision Support Intervention for Patients Offered Implantable Cardioverter-Defibrillators
• Bio-AffectDX: A-fib associated w/ HF treated by Biotronik's CRT-DX system.

Stroke Care:

• GERFHS-ROSE:  Genetic and Environmental Risk Factors for Hemorrhagic Stroke

How to Contact Us

For general questions about the research program at Baptist Health Louisville, please contact our clinical research manager:

Melissa Barnes
Manager, Research Regulatory
Phone: 859.260.6363
Email: melissa.barnes2@bhsi.com

If you are currently participating in a trial and have a question, please contact your study coordinator, your physician, or the physician overseeing your study. Contact information is included with the consent documents you signed when you enrolled in the trial.

Where We Are Located

Baptist Health Louisville Research Department

4003 Kresge Way

Suite 131

Learn more about Clinical Trials at Baptist Health.